Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Extension Study of Lanreotide (ITM-014) in Japanese Patients With Neuroendocrine Tumour
jRCT2080222647Phase 2Completed
- Sponsor
- Teijin Pharma
- Start
- Nov 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide in neuroendocrine tumour (NET), sponsored by Teijin Pharma. Started Nov 2014; status: completed.
02
Drugs
lanreotide
03
Conditions
neuroendocrine tumour (NET)
Beyond the preview
Go deeper on jRCT2080222647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222647.